Head-To-Head Analysis: Medgenics (NASDAQ:GNMX) vs. Windtree Therapeutics (WINT)

Windtree Therapeutics (OTCMKTS: WINT) and Medgenics (NASDAQ:GNMX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, profitability, valuation, risk, institutional ownership and earnings.

Insider and Institutional Ownership

6.6% of Windtree Therapeutics shares are held by institutional investors. Comparatively, 16.8% of Medgenics shares are held by institutional investors. 0.8% of Windtree Therapeutics shares are held by company insiders. Comparatively, 15.2% of Medgenics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Windtree Therapeutics and Medgenics’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Windtree Therapeutics $2.04 million 7.05 -$39.49 million ($71.80) -0.06
Medgenics N/A N/A -$41.90 million ($0.96) -2.23

Windtree Therapeutics has higher revenue and earnings than Medgenics. Medgenics is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Windtree Therapeutics and Medgenics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -1,205.47% N/A -345.52%
Medgenics N/A -163.88% -130.14%

Analyst Recommendations

This is a summary of recent recommendations and price targets for Windtree Therapeutics and Medgenics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 0 0 2.00
Medgenics 0 1 1 0 2.50

Medgenics has a consensus price target of $4.25, indicating a potential upside of 98.60%. Given Medgenics’ stronger consensus rating and higher probable upside, analysts clearly believe Medgenics is more favorable than Windtree Therapeutics.

Summary

Medgenics beats Windtree Therapeutics on 8 of the 11 factors compared between the two stocks.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Medgenics Company Profile

Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease. The company was formerly known as Medgenics, Inc. and changed its name to Aevi Genomic Medicine, Inc. in December 2016. Aevi Genomic Medicine, Inc. was founded in 2000 and is based in Wayne, Pennsylvania.

Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply